CNBCLean R·
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Read at CNBC →
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
<iframe src="https://statesidedaily.com/embed/cluster/0995ba6cd2d36584eb321d1030c9539757ba308b" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction"></iframe>